Hiro Clinic’s thoughts on NIPT

Hiro Clinic’s choice for the best NIPT test

We, the group companies including Hiro Clinic, are familiar with NIPT all over the world.

There are currently four main types of NIPT tests offered by various companies around the world. Each of these tests has its own advantages and disadvantages.

We have selected two excellent methods from which we have verified the testing methods and the credibility of the tests; the two are combined in a way that allows them to compensate for each other’s areas of deficiency. Instead of sending specimens to that selected testing method, the Group company’s hygiene laboratory (Tokyo Hygienic Laboratory) conducts domestic testing using the two methods after receiving a technology transfer.

We believe that the combination of the two testing methods provides the best NIPT test available at the moment. Performing the test itself means that we have to take great responsibility for the test results.

We always act with such a spirit.

Connecting achievements to the future

Even Down syndrome, the most common genetic disorder, is said to have a 1% incidence in pregnant women aged 40 years, and NIPT gives normal results in 97% of them. In other words, NIPT is a test for 3% of pregnant women.
However, we can imagine that the consequences of this have a not inconsiderable impact on the family and the individual.
Although most pregnant women have normal pregnancies from the point of view of the screening test, a variety of cases have been included, such as twins or vanishing twins. The variety of special cases has varied, even if their frequency is quite low.

We have already carried out more than 68,000 national inspections and have experienced rare test results that occur on a 10,000 person basis.
In such cases, looking only at the figures of the test results may not be enough. A test is a test and looking at just one event may not solve the problem.

Hiro Clinic has observed correlations in a complex manner by collecting clinical and amniotic fluid test results from pregnant women who have been seen by the clinic. For cases that we cannot resolve on our own, we collaborate with our partners, Illumina and Medicover, to carry out analyses that we could not do on our own.
By repeating these accumulations, we want to consider whether there are any similar cases from the past and provide the best possible outcome.

Finally,
We are proud to be a NIPT specialist group that is second to none. We believe that this is the result of the accumulation of cases one by one, and that repeating this process will make it even more certain.

医師監修 監修日:2023年4月15日
岡 博史 (医師・医学博士/ヒロクリニック統括院長)

日本皮膚科学会 皮膚科専門医/日本医師会 産業医/東京衛生検査所 指導監督医

この記事は、 ヒロクリニックNIPTの編集・監修体制 にもとづき、資格を持つ医師が内容を確認しています。